|
業務類別
|
Biotechnology |
|
業務概覽
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future. |
| 公司地址
| 7-11 boulevard Haussmann, Paris, FRA, 75009 |
| 電話號碼
| +33 153830963 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.abivax.com |
| 員工數量
| 69 |
| Mr. Marc de Garidel |
Chief Executive Officer and Director |
美元 600.60K |
23/03/2026 |
| Dr. Fabio Cataldi, M.D. |
Chief Medical Officer |
-- |
23/03/2026 |
| Mr. Didier Blondel |
Executive Vice President, Chief Financial Officer and Board Secretary |
-- |
23/03/2026 |
| Dr. Keith Fournier, PhD |
Senior Vice President, Global Regulatory Affairs |
-- |
23/03/2026 |
| Mr. Michael Nesrallah |
Chief Commercial Officer |
-- |
23/03/2026 |
| Dr. Maurus de la Rosa |
Senior Vice President, Research |
-- |
23/03/2026 |
|
|
| Mr. Troy A. Ignelzi |
Independent Director |
23/03/2026 |
| Dr. June Lee, M.D. |
Independent Director |
23/03/2026 |
| Ms. Corinna zur Bonsen-Thomas |
Independent Director |
23/03/2026 |
| Mr. Marc de Garidel |
Chief Executive Officer and Director |
23/03/2026 |
| Dr. Sylvie Gregoire,Pharm.D. |
Chairman of the Board |
23/03/2026 |
| Ms. Camilla Soenderby |
Independent Director |
23/03/2026 |
| Dr. Dominik Hochli, M.D. |
Independent Director |
23/03/2026 |
|
|
|
|
